

# Ruud H Brakenhoff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8737268/publications.pdf>

Version: 2024-02-01

88  
papers

6,541  
citations

172457

29  
h-index

66911

78  
g-index

90  
all docs

90  
docs citations

90  
times ranked

8671  
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations between clinical and histopathological characteristics in oral leukoplakia. <i>Oral Diseases</i> , 2023, 29, 696-706.	3.0	6
2	Oral leukoplakia classification and staging system with incorporation of differentiated dysplasia. <i>Oral Diseases</i> , 2023, 29, 2667-2676.	3.0	5
3	Age-group-specific trend analyses of oropharyngeal squamous cell carcinoma incidence from 1989 to 2018 and risk factors profile by age-group in 2015-2018: a population-based study in The Netherlands. <i>European Journal of Cancer Prevention</i> , 2022, 31, 158-165.	1.3	6
4	Study retention and attrition in a longitudinal cohort study including patient-reported outcomes, fieldwork and biobank samples: results of the Netherlands quality of life and Biomedical cohort study (NET-QUBIC) among 739 head and neck cancer patients and 262 informal caregivers. <i>BMC Medical Research Methodology</i> , 2022, 22, 27.	3.1	13
5	Secreted protein markers in oral squamous cell carcinoma (OSCC). <i>Clinical Proteomics</i> , 2022, 19, 4.	2.1	12
6	Unmet Needs and Perspectives in Oral Cancer Prevention. <i>Cancers</i> , 2022, 14, 1815.	3.7	14
7	Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , 1.	2.8	2
8	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide <scp>EU</scp> Project. <i>Head and Neck</i> , 2021, 43, 601-612.	2.0	18
9	The course of health-related quality of life from diagnosis to two years follow-up in patients with oropharyngeal cancer: does HPV status matter?. <i>Supportive Care in Cancer</i> , 2021, 29, 4473-4483.	2.2	14
10	The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma. <i>International Journal of Cancer</i> , 2021, 149, 420-430.	5.1	35
11	At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oral Health</i> , 2021, 2, 647980.	3.0	4
12	Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization. <i>Cancers</i> , 2021, 13, 2635.	3.7	19
13	Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. <i>Cancers</i> , 2021, 13, 2774.	3.7	11
14	A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. <i>Cancers</i> , 2021, 13, 3271.	3.7	12
15	The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis. <i>Oral Oncology</i> , 2021, 121, 105454.	1.5	4
16	NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11057.	4.1	4
17	Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus-Positive Oropharyngeal Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1666-1676.	3.0	6
18	889-... DuoBody®-CD3x5T4 induces efficient T-cell activation and killing of patient-derived head and neck cancer cells in vitro and ex vivo. , 2021, 9, A932-A932.		0

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Novel and Rapid Molecular Detection Method for High-Risk Human Papillomavirus in Formalin-Fixed, Paraffin-Embedded Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 262-271.	2.8	8
20	Incorporation of differentiated dysplasia improves prediction of oral leukoplakia at increased risk of malignant progression. <i>Modern Pathology</i> , 2020, 33, 1033-1040.	5.5	28
21	Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study. <i>Oral Oncology</i> , 2020, 110, 105014.	1.5	33
22	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 104-119.	6.9	51
23	Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 147, 186-194.	0.6	12
24	Outcome prediction of head and neck squamous cell carcinoma by MRI radiomic signatures. <i>European Radiology</i> , 2020, 30, 6311-6321.	4.5	49
25	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. <i>Scientific Reports</i> , 2020, 10, 4542.	3.3	46
26	Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2020, 147, 1732-1739.	5.1	6
27	Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer. <i>Oral Oncology</i> , 2020, 109, 104851.	1.5	3
28	Comprehensive multiparameter genetic analysis improves circulating tumor DNA detection in head and neck cancer patients. <i>Oral Oncology</i> , 2020, 109, 104852.	1.5	27
29	Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition. <i>Scientific Reports</i> , 2020, 10, 2330.	3.3	8
30	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. <i>PLoS ONE</i> , 2020, 15, e0232639.	2.5	35
31	Title is missing!. , 2020, 15, e0232639.		0
32	Title is missing!. , 2020, 15, e0232639.		0
33	Title is missing!. , 2020, 15, e0232639.		0
34	Title is missing!. , 2020, 15, e0232639.		0
35	Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC. <i>Cancer Research</i> , 2019, 79, 5597-5611.	0.9	28
36	Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass. <i>Oral Oncology</i> , 2019, 98, 53-61.	1.5	22

#	ARTICLE	IF	CITATIONS
37	Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients. <i>Cancers</i> , 2019, 11, 583.	3.7	28
38	Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death. <i>Oncogenesis</i> , 2019, 8, 38.	4.9	48
39	Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. <i>Journal of Proteomics</i> , 2019, 196, 106-119.	2.4	18
40	Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 7256-7265.	7.0	18
41	Establishment and Genetic Landscape of Precancer Cell Model Systems from the Head and Neck Mucosal Lining. <i>Molecular Cancer Research</i> , 2019, 17, 120-130.	3.4	25
42	ACE: absolute copy number estimation from low-coverage whole-genome sequencing data. <i>Bioinformatics</i> , 2019, 35, 2847-2849.	4.1	50
43	Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation. <i>Frontiers in Oncology</i> , 2019, 9, 1470.	2.8	19
44	The molecular landscape of head and neck cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 269-282.	28.4	897
45	Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. <i>British Journal of Radiology</i> , 2018, 91, 20170498.	2.2	109
46	Limited detection of human polyomaviruses in Fanconi anemia related squamous cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0209235.	2.5	7
47	Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection. <i>BMC Bioinformatics</i> , 2018, 19, 301.	2.6	12
48	A review of the most promising biomarkers for early diagnosis and prognosis prediction of tongue squamous cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 724-736.	6.4	95
49	Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. <i>Head and Neck</i> , 2017, 39, 840-852.	2.0	34
50	The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 540-550.	4.1	24
51	Risk Groups for Survival in HPV-Positive and HPV-Negative OPSCC. <i>Recent Results in Cancer Research</i> , 2017, 206, 221-231.	1.8	0
52	Molecular Patterns and Biology of HPV-Associated HNSCC. <i>Recent Results in Cancer Research</i> , 2017, 206, 37-56.	1.8	18
53	Improved high-dimensional prediction with Random Forests by the use of co-data. <i>BMC Bioinformatics</i> , 2017, 18, 584.	2.6	11
54	Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck. <i>Oncotarget</i> , 2017, 8, 97928-97940.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. <i>Oncotarget</i> , 2017, 8, 59312-59323.	1.8	22
56	Interaction of quantitative <sup>18</sup> F-FDG PET/CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 529-535.	2.0	23
57	Applications of molecular diagnostics for personalized treatment of head and neck cancer: state of the art. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 205-221.	3.1	11
58	Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs secondary primary tumor. <i>Oral Oncology</i> , 2015, 51, 738-744.	1.5	31
59	Prevalence of human papillomavirus in laryngeal and hypopharyngeal squamous cell carcinomas in northern Spain. <i>Cancer Epidemiology</i> , 2015, 39, 37-41.	1.9	44
60	Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1434-1444.	4.1	32
61	HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?. <i>Oral Oncology</i> , 2015, 51, 1057-1060.	1.5	21
62	Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function. <i>Nature Communications</i> , 2015, 6, 8399.	12.8	46
63	Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer. <i>Cancer Research</i> , 2015, 75, 3543-3553.	0.9	30
64	Noninvasive Molecular Screening for Oral Precancer in Fanconi Anemia Patients. <i>Cancer Prevention Research</i> , 2015, 8, 1102-1111.	1.5	18
65	Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. <i>European Journal of Cancer</i> , 2014, 50, 765-773.	2.8	79
66	Generation of precursor cell lines from preneoplastic fields surrounding head and neck cancers. <i>Head and Neck</i> , 2013, 35, 568-574.	2.0	14
67	Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. <i>Oral Oncology</i> , 2013, 49, 560-566.	1.5	63
68	Molecular screening of oral precancer. <i>Oral Oncology</i> , 2013, 49, 1129-1135.	1.5	58
69	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. <i>International Journal of Cancer</i> , 2013, 132, 1565-1571.	5.1	177
70	Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1994-2003.	7.0	69
71	Potentially novel options for treatment of HPV-attributable head and neck cancer. <i>Cell Cycle</i> , 2013, 12, 1020-1020.	2.6	0
72	DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e61555.	2.5	34

#	ARTICLE	IF	CITATIONS
73	Response to correspondence on the molecular biology of head and neck cancer. Nature Reviews Cancer, 2011, 11, 382-382.	28.4	10
74	The molecular biology of head and neck cancer. Nature Reviews Cancer, 2011, 11, 9-22.	28.4	2,151
75	Prognostic value of DNA ploidy status in patients with oral leukoplakia. Oral Oncology, 2011, 47, 956-960.	1.5	64
76	Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. International Journal of Cancer, 2011, 128, 1852-1859.	5.1	48
77	Another NOTCH for Cancer. Science, 2011, 333, 1102-1103.	12.6	25
78	Genetic Classification of Oral and Oropharyngeal Carcinomas Identifies Subgroups with a Different Prognosis. Analytical Cellular Pathology, 2009, 31, 291-300.	1.4	5
79	A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. International Journal of Cancer, 2007, 121, 2465-2472.	5.1	658
80	Generation and Molecular Characterization of Head and Neck Squamous Cell Lines of Fanconi Anemia Patients. Cancer Research, 2005, 65, 1271-1276.	0.9	76
81	Genetically Altered Fields as Origin of Locally Recurrent Head and Neck Cancer. Clinical Cancer Research, 2004, 10, 3607-3613.	7.0	163
82	Molecular Diagnosis of Surgical Margins and Local Recurrence in Head and Neck Cancer Patients. Clinical Cancer Research, 2004, 10, 3614-3620.	7.0	152
83	Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions. Head and Neck, 2002, 24, 198-206.	2.0	265
84	Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. International Journal of Cancer, 2001, 92, 661-665.	5.1	28
85	Minimal residual disease in head and neck cancer. , 1999, 18, 109-126.		51
86	Characterization of cd44v6 isoforms in head-and-neck squamous-cell carcinoma. , 1999, 82, 837-845.		33
87	BIOLOGIC IMPLICATIONS OF GENETIC CHANGES IN HEAD AND NECK SQUAMOUS CELL CARCINOGENESIS. ANZ Journal of Surgery, 1997, 67, 410-416.	0.7	9
88	Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. , 1996, 68, 520-527.		35